Study details
Enrolling now
Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia
Massachusetts General Hospital
NCT IDNCT07238400ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
90
Study length
about 3.3 years
Ages
18–55
Sex
Female only
Locations
2 sites in MA
About this study
Researchers are testing whether eplerenone, a medication, improves coronary microvascular function better than chlorthalidone in women who had preeclampsia. The trial will last 1215 days and involve taking either eplerenone + potassium or chlorthalidone + potassium daily for 48 weeks.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Chlorthalidone 25 mg daily
- 2.Take Eplerenone 100 mg daily
- 3.Take Potassium Chloride
- +1 more
PhasePhase 2
DrugChlorthalidone 25 mg daily
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
chlortalidone, eplerenone, potassium chloride
Drug routes
oral (Oral Tablet)
Body systems
Cardiology / Heart